Our New Alert Is

TNIB – TNI BioTech, Inc.

TNI BioTech Inc. is a biotech company combating fatal diseases through the activation and mobilization of the body’s immune system using patented immunotherapy technology.

TNIB‘s products and technologies are designed to harness the power of the immune system to improve the treatment and diagnosis of cancer, infections such as HIV/AIDS and autoimmune diseases.

TNIB‘s proprietary technology, therapies and patents, will be used to treat a wide range of cancers.

TNIB‘s most advanced clinical programs involve immunotherapy that works by isolating a patient’s lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient’s lymphocytes are reinfused back into the patient where they combat and destroy tumor cells.

Based on NCI’s SEER Cancer Statistics Review it is estimated that 1,638,910 men and women (848,170 men and 790,740 women) will be diagnosed with and 577,190 men and women will die of cancer of all sites in 2012.

TNIBthose diagnosed with all forms of cancer through their patented immunotherapy technology.

The Immunotherapy Advantage

Immunotherapy presents a number of potential advantages over approved cancer treatments. The traditional tools for treating cancer have been around for years, radiation since the 1800, chemotherapy that evolved from the use mustard gas after World War I and surgery. All of these treatments are based upon destroying the cells either by damaging their DNA, selective toxicity or removing them. All of these therapies have a high order of side effects. Immunotherapy goal is to treat the disease by avoiding the necessity for these traditional treatments.

The immune system is a diverse one with three major biological functions, that is (1) immune defense which works against infectious organisms such as bacteria, viruses, fungi, parasites; (2) immune homeostasis which works to remove senescent cells and debris; and (3) immune surveillance to clear mutated cell or cancer cell.

Researchers discovered that the principal cells in the immune system that attacked viruses and tumors were Macrophage, DC cells, T cells, NK cells, NKT cells and Gammadelta T cells. These cells originate in bone marrow and play functions in peripheral blood or immune organs.

The most important participant in the immune response is a class of white blood cells known as lymphocytes. These cells develop in the bone marrow and are released into general circulation. There are mainly different subpopulations of T Cells: Helper T Cells (Th) (CD4+), CytotoxicT Cells (CTL)(CD8+) and CD4+CD25+T cells (Treg).

One of the most significant medical advances in the past twenty years is the discovery of the hormones of the immune system, known as “cytokines”. Cytokines are small proteins or polypeptides produced by certain body cells that interact with other cells of the immune system in order to regulate the body’s response to disease or other disorder.

The most famous of these are the interleukins (IL) and the interferons, such as IL2 and gamma interferons. Another major group includes the enkephalins such as methionine met-enkephalin (MENK) and endorphins that regulate not only the cells of the immune system but also those of the endocrine system keeping the two in balance. Clinically, these cytokines have been found to be useful in stimulating the immune system and in treating viral infections such as HIV/AIDS, hepatitis as well as in numerous types of cancers.

MENK, the endogenous neuropeptide generated in the adrenal gland and derived from proenkephalin is suggested to be involved in the regulatory loop between the immune and neuroendocrine systems, with modulation of various functions of cells related to both innate and adaptive immune systems.

Two of the most important compounds to come out the current research for TNIB are LDN (Low Dose Naltrexone) and MENK (Methionine Enkephalin). Both LDN and MENK in a combinational way are proven immune- enhancing drugs with synergism. They boost the immune system by increasing the T and NK cells in the body, thereby activating its own natural defenses.

TNIB’s Products Include

IRT-101 is an active immunotherapy that works by activating a patient’s immune system against infectious diseases and tumor cells. This is accomplished by increasing the number of T cells and NK cells, NKT and Gammadelta T cells that destroy infective organisms and tumor cells while simultaneously inhibiting Treg cells.

IRT-102 is an adaptive immunotherapy that works by isolating and enriching a patient’s own immune cells and following an enriching external incubation are transfused back into the patient thereby providing the patient with a passive immunity containing large amounts of auto-amplified immune cells that combat cancer cells.

IRT- 103 is an active immunotherapy that works by activating a patient’s immune system against HIV/AIDS and tumor cells. This is accomplished by activating the enkephalin receptor system resulting in increased number of T cells and NK cells that destroy infective organisms and tumor cells.

However, since any condition that results in an altered-immune response is a potential target for investigation. The Company intends to investigate the following valuable candidates:

• Autoimmune states such as rheumatoid arthritis and multiple sclerosis.
• As an adjuvant to vaccines in the protection from getting infectious diseases
• In patients undergoing chemotherapy or radiation treatments in surgery
• In wound healing, herpes and shingles in the elderly.

In clinical trials the evidence is significant that LDN/MENK stimulates the immune system and that it is effective in the treatment of some immune-suppressed diseases. The treatment modality has been demonstrated to be effective while avoiding certain deleterious effects on the body, as is often the case with traditional chemotherapy. The costs are reasonable, making this an attractive complement for a large number of cancer patients

Make sure to reseach TNIB very closely tonight & for additional information visit their website athttp://tnibiotech.com

We believe TNIB could end 2012 as being one of our most successful alerts of the year so stay tuned for further updates tonight!

Happy Trading,

TerrificPennyStocks.com

Follow Us On Twitter @TerrificPenny